

INFORMAZIONI PERSONALI

Peter Marschang

📍 Divisione di Medicina Interna, Ospedale di Bolzano, Via Boehler 5

☎ [REDACTED]

📧 [REDACTED]

📅 Data di nascita 1965

ESPERIENZA LAVORATIVA

Da 07 / 2018 Direttore della Divisione di Medicina Interna, Ospedale di Bolzano

09 / 2003 – 06 / 2018 Dirigente medico, Divisione di Medicina Interna, Università di Medicina di Innsbruck, Austria

03 / 2003 – 08 / 2003 Postdoctoral fellow, Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, USA

03 / 2001 – 02 / 2003 Borsa di studio „Erwin Schrödinger“ del fondo per il promovimento della ricerca scientifica (FWF), Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, USA

1995 – 2001 Medico in formazione specialistica, Divisione di Medicina Interna, Università Leopold Franzens di Innsbruck, Austria

1992 – 1995 Medico in formazione specialistica, Istituto di Igiene, Università Leopold Franzens di Innsbruck, Austria

1992 Borsa di studio „Fulbright“, Dana Farber Cancer Institut, Boston, USA

1990 – 1992 Collaboratore scientifico, Istituto Ludwig Boltzmann per la ricerca sull' AIDS, Innsbruck, Austria

ISTRUZIONE E FORMAZIONE

2023. Istruttore di ecografia (addome, arterie e vene periferici, arterie cerebrali extra cranici), Società di ultrasonografia Austriaca (ÖGIM)

2021 – 2022. Corso di management, Azienda sanitaria di Bolzano

2015 Specializzazione in Cardiologia, Università di Medicina di Innsbruck, Austria

2009 – 2010 Corso d'insegnamento per i direttori medici, Università di Medicina privata Paracelsus, Salzburg, Austria

2008 Specializzazione in Endocrinologia e Malattie del Metabolismo, Università di Medicina di Innsbruck, Austria

2006 L'attestazione di qualifica in Ecocardiografia, Università di Medicina di Innsbruck, Austria

2007 Specializzazione in Angiologia, Università di Medicina di Innsbruck, Austria

2006 Abilitazione alla libera docenza in Medicina Interna, Associate Professor, Università di Medicina di Innsbruck, Austria

2006 Diploma di sperimentazione clinica, Ordine dei Medici del Tirolo

2001 Specializzazione in Medicina Interna, Università Leopold Franzens di Innsbruck, Austria

1998 Specializzazione in Igiene e Microbiologia, Università Leopold Franzens di Innsbruck, Austria

1991 Formazione di base per gli amministratori delegati per la radioprotezione, Istituto per il pro-movimento della economia della Camera del Commercio di Innsbruck

1990 Promozione (Dr. med.univ), titolo della tesi: „Kreuzreaktionen zwischen dem Glykoprotein gp120 des humanen Immundefizienzvirus Typ 1 und humanem Immunglobulin G: Molekulares Mimikry am Beispiel des HIV-1“

1983-1990 Studi di Medicina presso l'Università Leopold Franzens di Innsbruck, Austria

1983 Esame di maturità con lode, liceo classico, Innsbruck.

CAPACITÀ E COMPETENZE

Madrelingua Tedesco

Altra Lingua

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Letture	Interazione	Produzione orale	
Italiano	C1	C1	C1	C1	C1
Certificato PLIDA C1 – attestato di bilinguismo Provincia di Bolzano					
Inglese	C1	C1	C1	C1	C1

Capacità e competenze scientifiche

Numerose pubblicazioni scientifiche, conferenze scientifiche, reviewer per riviste medicinali internazionali, membro delle associazioni nazionali ed internazionali.
Effettuazione di numerose sperimentazioni cliniche accademiche e sponsorizzate dalla industria come ricercatore principale (EINSTEIN-DVT, EINSTEIN-PE, EINSTEIN-EXT, AMPLIFY, AMPLIFY-EXT,

HOKUSAI, XALIA, PREFER in VTE, EINSTEIN-CHOICE)

Dirigenza di un gruppo di lavoro scientifico (recettori delle lipoproteine)

Applicazione di successo per i grant competitivi (fondo per il promovimento della ricerca scientifica (FWF) proposta P20825-805, role of LRP1b in cancer and atherosclerosis, fondo del anniversario della banca nazionale Austriaca progetto 16666, correlation of atherosclerotic plaque volume and intima media thickness with soluble P-selectin)

Capacità e Competenze organizzative e dirigente

Attualmente direttore del reparto di Medicina Interna (109 letti) dell'ospedale di Bolzano, responsabile per 35 dirigenti medici

Dirigenza del ambulatorio angiologico 2010 – 2012 und 2016 – 06/2018, Dirigenza del centro per la sperimentazione clinica come ricercatore principale, Dirigenza di un gruppo di lavoro scientifico (Università di Medicina di Innsbruck)

Membro della conferenza dipartimentale, membro della conferenza per la assicurazione di qualità decentrale (Ospedale di Innsbruck)

Capacità e competenze didattiche

Lezioni e corsi per studenti di Medicina, istruzione dei dottorandi, incarico d'insegnamento alla accademia dietetica, incarico d'insegnamento all'Università Leopold Franzens di Innsbruck (istituto di farmacia), corsi di ecografia certificati (ÖGUM)

Pubblicazioni

Stanworth DR, Sölder B, Lewin IV, Nayyar S, **Marschang P**, Wachter H, Dierich MP. Related epitopes in HIV viral coat protein and human IgG. *Lancet*. 1989 Jun 24;1(8552):1458-9.

Sölder B, **Marschang P**, Wachter H, Dierich MP, Nayyar S, Lewin IV, Stanworth DR. Anti-viral antibodies in HIV (HTLV-III) infection possess auto-antibody activity against a CH1 domain determinant in human IgG: possible immunological consequences. *Immunol Lett*. 1989 Nov;23(1):9-19

Ebenbichler CF, Thielens NM, Vornhagen R, **Marschang P**, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. *J Exp Med*. 1991 Dec 1;174(6):1417-24.

Dierich MP, **Marschang P**, larcher C. HIV and human complement: Molecular mechanisms and biological consequences. *Progress in Immunology* 1992; 8:691-698.

Marschang P, Gürtler L, Tötsch M, Thielens NM, Arlaud GJ, Hittmair A, Katinger H, Dierich MP. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. *AIDS*. 1993 Jul; 7(7):903-10.

Dierich MP, Ebenbichler CF, **Marschang P**, Füst G, Thielens NM, Arlaud GJ. HIV and human complement: mechanisms of interaction and biological implication. *Immunol Today*. 1993 Sep;14(9):435-40. Review

Erdei A, Julen N, **Marschang P**, Feifel E, Kerekes K, Dierich MP. A novel, complement factor H-related regulatory protein expressed on the surface of human B cell lines. *Eur J Immunol*. 1994 Apr;24(4):667-72

Marschang P, Ebenbichler CF, Dierich MP. HIV and complement: role of the complement system in HIV infection. *Int Arch Allergy Immunol*. 1994;103(2):113-7.

Dierich MP, **Marschang P**, Stoiber H, larcher C. HIV and complement. In Erdei A (ed.): *New aspects of complement structure and function*. Landes, Austin 1994, 151 – 160.

Marschang P, Sodroski J, Würzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. *Eur J Immunol*. 1995 Jan; 25(1):285-90.

Marschang P, Krüger U, Ochsenbauer C, Gürtler L, Hittmair A, Bosch V, Patsch JR, Dierich MP. Complement activation by HIV-1-infected cells: the role of transmembrane glycoprotein gp41. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1997 Feb 1; 14(2):102-9.

Friedrich GJ, Moes N, Mühlberger V, Neumayr G, Metzler B, **Marschang P**, Pachinger O. Die Erkennung von myokardialer Ischämie nach koronarer Ballonangioplastie durch kardiale Troponin-T Schnelltest Bestimmungen. *Perfusion* 1999; 12:4-8

Gaenzler H, Neumayr G, **Marschang P**, Sturm W, Kirchmair R, Patsch JR. Flow-mediated vasodilation of the femoral and brachial artery induced by exercise in healthy nonsmoking and smoking men. *J Am Coll Cardiol*. 2001 Nov 1;38(5):1313-9

Gaenzler H, Neumayr G, **Marschang P**, Sturm W, Lechleitner M, Föger B, Kirchmair R, Patsch J. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. *Am J Cardiol*. 2002 Feb 15; 89(4):431-4.

Kähler CM, Schratzberger P, Kaufmann G, Hochleitner B, Bechter O, Götsch C, Wöl E, **Marschang P**, Herold M, Wiedemann CJ. Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin. *Regulatory Peptides* 2002; 105:35-46.

Gaenzler H, **Marschang P**, Sturm W, Neumayr G, Vogel W, Patsch J, Weiss G. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. *J Am Coll Cardiol*. 2002 Dec 18;40(12):2189-94

Marschang P, Herz J. Mouse models as tools for dissecting disorders of lipoprotein metabolism. *Semin Cell Dev Biol*. 2003 Feb; 14(1):25-35.

Herz J, **Marschang P**. Coaxing the LDL receptor family into the fold. *Cell*. 2003 Feb 7;112(3):289-92

Marschang P, Blich J, Weeber EJ, Sweatt JD, Shelton JM, Richardson JA, Hammer RE, Herz J. Normal development and fertility of knockout mice lacking the tumor suppressor gene LRP1b suggest functional compensation by LRP1. *Mol Cell Biol*. 2004 May;24(9):3782-93

Marschang P, Friedrich GJ, Dittbacher H, Stoeger A, Nedden DZ, Kirchmair R, Dienstl A, Pachinger O, Patsch JR. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. *Int J Cardiol*. 2006 Jan 13;106(2):183-90

Marschang P, Götsch C, Kirchmair R, Kaser S, Kähler CM, Patsch JR. Postprandial, but not postabsorptive low-density lipoproteins increase the expression of intercellular adhesion molecule-1 in human aortic endothelial cells. *Atherosclerosis*. 2006 May;186(1):101-6

Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. *J Intern Med*. 2006 Aug; 260(2):151-9.

Pechlaner C, **Marschang P**. Dabigatran versus enoxaparin after total hip replacement. *Lancet* 2007; 370:2002.

Marschang P, Niederwanger A, Gasser RW, Daniaux M, Sturm W. Symptomatic upper extremity deep vein thrombosis as a complication of ambulatory blood pressure monitoring. *Thromb Haemost*. 2008 Oct;100(4):711-

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*. 2010 Dec 23

Haas J, Beer AG, Widschwendter P, Oberdanner J, Salzmann K, Sarg B, Lindner H, Herz J, Patsch JR, **Marschang P**. LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE-carrying lipoproteins. *Atherosclerosis*. 2011 Jun; 216(2):342-7.

Marschang P. Deep vein thrombosis of the arms. In G. Cheng (ed) *Deep vein thrombosis*. Intech 2012; 129 - 42

Kaehler ST, Baumgartner H, Jeske M, Anliker M, Schennach H, **Marschang P**, Ratt A, Colvin AC, Falk J, Gasser A, Kirchbner J, Scherer C, Purtscher AE, Griesmacher A, Striessnig

J. Prevalence of hypovitaminosis D and folate deficiency in healthy young female Austrian students in a health care profession. *Eur J Nutr.* 2012 Dec; 51(8):1021-31

EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012; 366:1287-97.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; **AMPLIFY-EXT Investigators**. Apixaban for extended treatment of venous thromboembolism. *N Engl J Med* 2013; 368:699-708.

Kirchmair R., **Marschang P**, Medical therapy for peripheral vascular disease. In Minar E, Schillinger M. (ed) *Peripheral vascular disease: basic & clinical perspectives*. Future Medicine, London 2013; 49-59

Watzke H, Metzler H, Weltermann A, **Marschang P**, Brodmann M, Lang W, Pabinger-Fasching I, Mahla E, Kozek-Langenecker S, Guschmann M, Huber K. Periprocedural management of vitamin K antagonists with low molecular weight heparins during invasive procedures—Consensus of experts. *Wien Klin Wochenschr.* 2013 Jul; 125(13-14):412-20.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; **AMPLIFY Investigators**. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013; 369:799-808.

Hokusai-VTE Investigators, Büller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwach L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med* 2013; 369:1406-15.

Kleinjan A, Di Nisio M, Beyer-Westendorf J, Camporese G, Cosmi B, Ghirarduzzi A, Kamphuisen PW, Otten HM, Porreca E, Aggarwal A, Brodmann M, Guglielmi MD, Iotti M, Kaasjager K, Karvissi V, Lerede T, **Marschang P**, Meijer K, Palareti G, Rickles FR, Righini M, Rutjes AW, Tonello C, Verhamme P, Werth S, van Wissen S, Büller HR. Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. *Ann Intern Med.* 2014 Apr 1; 160(7):451-7.

Theurl M, Schgoer W, Albrecht-Schgoer K, Lener D, Wolf D, Wolf M, Demetz E, Tymoszuk P, Tancevski I, Fischer-Colbrie R, Franz WM, **Marschang P**, Kirchmair R. Secretoneurin gene therapy improves hind limb and cardiac ischaemia in Apo E^{-/-} mice without influencing systemic atherosclerosis. *Cardiovasc Res.* 2015 Jan 1; 105(1):96-106.

Missmann M, Himsl M, Mur E, Ulmer H, **Marschang P**. Impact of Whole Body Cryotherapy at -110 °C on Subjects with Arterial Hypertension. *Arch Immunol Ther Exp (Warsz).* 2015 Feb; 64(1):75-82.

Bleker SM, van Es N, Kleinjan A, Büller HR, Kamphuisen PW, Aggarwal A, Beyer-Westendorf J, Camporese G, Cosmi B, Gary T, Ghirarduzzi A, Kaasjager K, Lerede T, **Marschang P**, Meijer K, Otten HM, Porreca E, Righini M, Verhamme P, van Wissen S, Di Nisio M. Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis. *J Thromb Haemost.* 2016 May; 14(5):973-81.

Reindl M, Reinstadler SJ, Feistritzer HJ, Mayr A, Klug G, **Marschang P**, Metzler B. Acute myocardial infarction as a manifestation of systemic vasculitis. *Wien Klin Wochenschr.* 2016 Nov; 128(21-22):841-843.

Beer AG, Zenzmaier C, Schreinlechner M, Haas J, Dietrich MF, Herz J, **Marschang P**. Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member. *Oncotarget.* 2016 Oct 18; 7(42)

Schreinlechner M, Theurl M, Kirchmair R, Wolfgang-Michael Franz WM, **Marschang P**. (2016) Anticoagulation with rivaroxaban after ultrasound-assisted catheter-directed

thrombolysis in patients with intermediate highrisk pulmonary embolism—a case series. *Interv. Cardiol.* 2016; 8: 725–730

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Bayer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. *N Engl J Med.* 2017;376 :1211-1222

Noflatscher M, Luger AK, Frank R, Glodny B, Gruber J, Marschang P. Incidental finding of an absent left common carotid artery. *Vasa* 2018 47:153-155.

Brenner C, Margreiter J, Graf A, Klocker J, Kirchmair R, Marschang P, Friedrich G, Metzler B, Moes N. Femoral access site closure without prior femoral angiography : A retrospective analysis. *Wien Klin Wochenschr.* 2018; 130:197-203.

Noflatscher M, Moes N, Gassner EM, Marschang P. Dabigatran added to dual antiplatelet therapy to treat a left ventricular thrombus in a 87 year old patient with myocardial infarction and very high bleeding risk. *Front Pharmacol.* 2018; 9:217.

Noflatscher M, Schreinlechner M, Sommer P, Kerschbaum J, Berggren K, Theurl M, Kirchmair R, Marschang P. Influence of Traditional Cardiovascular Risk Factors on Carotid and Femoral Atherosclerotic Plaque Volume as Measured by Three-Dimensional Ultrasound. *J Clin Med.* 2019; 8:32.

Schreinlechner M, Noflatscher M, Kremser C, Steiger R, Grömer J, Theurl M, Kirchmair R, Mayr A, Marschang P. A Large Bifurcation Angle Is Strongly Associated With Increased Plaque Volume and Plaque Progression. *JACC Cardiovasc Imaging.* 2019, 12: 2087-2088.

Weber T, Arbeiter K, Ardelt F, Auer J, Aufricht C, Brandt MC, Dichtl W, Ferrari J, Föger B, Henkel M, Hohenstein-Scheibenecker K, Horn S, Kautzky-Willer A, Kepplinger E, Knoflach M, Koppelstätter C, Mache C, Marschang P, Mayer G, Metzler B, Oberbauer R, Obermair F, Obermayer-Plötsch B, Perl S, Pilz S, Prischl FC, Podczeczek-Schweighofer A, Rebhandl E, Rohla M, Roller-Wimmsberger R, Saely CH, Siostrzonek P, Slany J, Stoschitzky K, Waldegger S, Wenzel RR, Weiss T, Wirmsberger G, Winhofer-Stöckl Y, Zweiker D, Zweiker R, Watschinger B. Austrian Consensus on high blood pressure. *Wien Klin Wochenschr* 2019, 131(Suppl 6):489-590

Schreinlechner M, Noflatscher M, Reinstadler SJ, Sommer P, Lener D, Reiser E, Theurl M, Kirchmair R, Bauer A, Marschang P. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. *Atherosclerosis.* 2020, 297:25-31.

Schreinlechner M, Noflatscher M, Lener D, Bauer A, Kirchmair R, Marschang P, Theurl M. NGAL Correlates with Femoral and Carotid Plaque Volume Assessed by Sonographic 3D Plaque Volumetry. *J Clin Med.* 2020, 9:2811.

Gerotziapas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Clinic DM, Farkas K, Elalamy I, Falanga A, Fareed J, Papageorgiou C, Arellano RS, Agathagelou P, Antic D, Ausd L, Banfic L, Bartolomew JR, Benczur B, Bernardo MB, Boccardo F, Cilkova R, Cosmi B, De Marchi S, Dimakakos E, Dimopoulos MA, Dimitrov G, Durand-Zaleski I, Edmonds M, El Nazar EA, Erer D, Esponda OL, Gesele P, Gschwandtner M, Gu Y, Heinzmann M, Hamburg NM, Hamadé A, Jatou NA, Karahan O, Karetova D, Karplus T, Klein-Weigel P, Kolossvary E, Kozak M, Lefkou E, Lessiani G, Liew A, Marcoccia A, Marschang P, Marakomichelakis G, Matuska J, Moraglia L, Pilon S, Poradoc P, Prior M, Salvador DRK, Schlager O, Schemthaner G, Sieron A, Spaak J, Spyropoulos A, Spyringer M, Suput D, Stanek A, Stvrinova V, Szuba A, Tafur A, Vandredon P, Vardas PE, Vasic D, Viikula M, Wennberg P, Zhai Z; Scientific Reviewer Committee. Guidance for the Management of Patients with Vascular Disease or Cardio-vascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. *Thromb Haemost.* 2020; 120:1597-1628.

Noflatscher M, Schreinlechner M, Sommer P, Deuling P, Theurl M, Kirchmair R, Bauer A, Marschang P. Association of food and alcohol consumption with peripheral atherosclerotic plaque volume as measured by 3D-ultrasound. *Nutrients.* 2020; 12:3711.

Noflatscher M, Schreinlechner M, Sommer P, Kerschbaum J, Theurl M, Kirchmair R, Bauer A, Marschang P. Effect of gender and chronic kidney disease on carotid and femoral plaque volume as measured by three-dimensional ultrasound. *Clin Nephrol.* 2021 96:199-205.

Thüle K, Giacomuzzi K, Jani E, **Marschang P**, Mueller T. Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions. *Scand J Clin Lab Invest. Scand J Clin Lab Invest.* 2021; 81:461-468.

Buda E, Sorbo AR, Ferro F, **Marschang P**. Multiple vascular occlusions in a COVID-19 patient. *Eur Heart J Cardiovasc Imaging.* 2021 Aug 3; jeab152.

Cosmi B, Stanek A, Kozak M, Wennberg PW, Kolluri R, Righini M, Porados P, Lichtenberg M, Catalano M, De Marchi S, Farkas K, Gesele P, Klein-Wegol P, Lessiani G, **Marschang P**, Pecavarady Z, Prior M, Puskas A, Szuba A. The Post-thrombotic Syndrome-Prevention and Treatment: VAS-European Independent Foundation in Angiology/Vascular Medicine Position Paper. *Front Cardiovasc Med.* 2022; 9: 762443.

Sommer P, Schreinlechner M, Noflatscher M, Lener D, Mair F, Theurl M, Kirchmair R, **Marschang P**. High baseline fetuin-A levels are associated with lower atherosclerotic plaque progression as measured by 3D ultrasound. *Atherosclerosis Plus.* 2021; 45: 10-17.

Dimakakos E, Gomatou G, Catalano M, Olinic DM, Spyropoulos AC, Falanga A, Maraveyas A, Liew A, Schulman S, Belch J, Gerotziakas G, **Marschang P**, Cosmi B, Spaak J, Syrigos K. Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art. *Anticancer Res.* 2022 Jul;42(7):3261-3274.

Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, Catalano M, Spyropoulos AC, Schulman S, Douketis J, Falanga A, Maraveyas A, Olinic DM, Belch J, Gerotziakas G, Syrigos K, Kollias A; COVID-19 Thrombosis Collaborative Group. Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. *J Clin Med.* 2022 ;11(20):5997.

Progetti correnti

Characterization of LRP1b, a lipoprotein receptor of the LDL receptor family, using expression of a recombinant full-length receptors in human cells.
 Hemodynamic and geometric factors in atherosclerosis (ANGLE), NCT 03044704
 Atherosclerosis progression in coronary arteries compared to peripheral vessels (APRICOTS), NCT 03164174
 Correlation of the peripheral atherosclerotic burden with the short-term and long-term outcome in patients with elective myocardial revascularisation (ByPlaque), NCT03774004.

L'appartenenze

Österreichische Gesellschaft für Internistische Angiologie (ÖGIA), da 2014 nel comitato esecutivo, presidente (2018/2019)
 Österreichische Gesellschaft für Innere Medizin (ÖGIM)
 Österreichische Gesellschaft für Ultraschall in der Medizin (ÖGUM)
 European Atherosclerosis Society
 VAS European Independent Foundation in Angiology / Vascular medicine (board member)